Tetra Radar · Company Timeline
Replimune Group Inc (REPL)
Sector: Health Care
Earlier observations
- · FDA approval. The FDA approved TUDRIQEV in combination with nivolumab for treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Observations from the last 30 days, with Clusters and Heat Signatures, are in the Tetra Radar Library.
Dates are event dates. Tetra Radar observes public information for research purposes. It does not provide investment advice.